Chinese startup NeuroXess' new BCI can decipher the complex Chinese language in brain, operate a robotic arm and interact with AI.

With funding, resources, and collaboration, experts can improve their analysis and help patients. How are ECOG-ACRIN and Caris Life Sciences teaming up to fight cancer? Their recent announcement will ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Chinese startup NeuroXess on Thursday reported two significant clinical-trial milestones its flexible brain-computer interface BCI device successfu ...

Fenske, MD led ECOG-ACRIN EA4151, the first randomized trial to compare treatment with or without stem cell transplant in patients with MRD-negative mantle cell lymphoma in first complete remission.

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...

Innovative e-tattoo neurotech that prints directly on the scalp may be a game-changer for precision medicine, neuroscience, ...

In ECOG-ACRIN E5194, researchers examined the outcomes of patients with both higher-risk and “good-risk” DCIS who did not receive radiotherapy. In both studies, all patients were permitted to ...

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...